Effect of Banxia Xiexintang-containing Intestinal Absorption Solution on Migration and Invasion of PMN-MDSCs in Gastric Cancer Microenvironment

WEI Jingjing; ZHU Zhongbo; LIU Xiping; LI Peiqing; CHEN Qiming; DAI Lirong; SHI Lijuan; DUAN Haijing; WANG Qingmiao

doi:10.13422/j.cnki.syfjx.202202221

您当前的位置：

首页 >

文章列表页 >

Effect of Banxia Xiexintang-containing Intestinal Absorption Solution on Migration and Invasion of PMN-MDSCs in Gastric Cancer Microenvironment

更新时间：2023-04-13

- Effect of Banxia Xiexintang-containing Intestinal Absorption Solution on Migration and Invasion of PMN-MDSCs in Gastric Cancer Microenvironment
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 10, Pages: 48-57(2023)
- 作者机构：
  
  1.甘肃中医药大学甘肃省中药新产品创制工程实验室，甘肃省中医方药挖掘与创新转化重点实验室，兰州 730000
  2.兰州大学第一医院，兰州 730013
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.202202221
  CLC： R22;R242;R2-031;R285.5
- Published：20 May 2023，
  
  Published Online：20 July 2022，
  
  Received：28 April 2022，
- 稿件说明：
扫描看全文
魏晶晶,朱中博,刘喜平等.半夏泻心汤含药肠吸收液对胃癌微环境中PMN-MDSCs迁移侵袭的影响[J].中国实验方剂学杂志,2023,29(10):48-57.

WEI Jingjing,ZHU Zhongbo,LIU Xiping,et al.Effect of Banxia Xiexintang-containing Intestinal Absorption Solution on Migration and Invasion of PMN-MDSCs in Gastric Cancer Microenvironment[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(10):48-57.
魏晶晶,朱中博,刘喜平等.半夏泻心汤含药肠吸收液对胃癌微环境中PMN-MDSCs迁移侵袭的影响[J].中国实验方剂学杂志,2023,29(10):48-57. DOI： 10.13422/j.cnki.syfjx.202202221.

WEI Jingjing,ZHU Zhongbo,LIU Xiping,et al.Effect of Banxia Xiexintang-containing Intestinal Absorption Solution on Migration and Invasion of PMN-MDSCs in Gastric Cancer Microenvironment[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(10):48-57. DOI： 10.13422/j.cnki.syfjx.202202221.

摘要

目的

观察半夏泻心汤含药肠吸收液对胃癌微环境中多形核髓系来源抑制细胞（PMN-MDSCs）迁移侵袭的影响。

方法

制备含生药量0.63 g·mL

-1

的半夏泻心汤含药肠吸收液，以Transwell小室将胃癌细胞与PMN-MDSCs非接触共培养建立胃癌微环境模型，采用细胞增殖与活性检测-8（CCK-8）法筛选半夏泻心汤含药肠吸收液对PMN-MDSCs的最佳干预浓度及时间，用于后续实验，分为空白组、模型组、FAK抑制剂组及半夏泻心汤组（26%、18%、10%半夏泻心汤含药肠吸收液），采用细胞划痕实验和Transwell实验检测PMN-MDSCs的迁移和侵袭能力，酶联免疫吸附测定法（ELISA）检测肿瘤微环境中血管内皮细胞生长因子（VEGF）、基质金属蛋白酶-9（MMP-9）细胞因子表达，蛋白免疫印迹法（Western blot）检测PMN-MDSCs通路相关蛋白局部黏着斑激酶（FAK）、磷酸化（p）-FAK、蛋白酪氨酸激酶（Src）、磷酸化（p）-Src蛋白表达水平。

结果

与24 h比较，作用48 h 5%、50%、75%、100%半夏泻心汤含药肠吸收液对PMN-MDSCs的抑制率均有升高（

0.05，

0.01），与作用48 h比较，培养72 h 50%半夏泻心汤含药肠吸收液对PMN-MDSCs的抑制率低于48 h（

0.01），5%、100%半夏泻心汤含药肠吸收液略高于48 h（

0.05，

0.01），其余浓度抑制率差异无统计学意义，且48 h半数抑制浓度（IC

）为18.09%，说明18%半夏泻心汤含药肠吸收液在48 h为最佳干预浓度及时间；与空白组比较，模型组PMN-MDSCs迁移距离显著增大（

0.01），迁移及侵袭数量显著增多（

0.01）；与模型组比较，FAK抑制剂组、半夏泻心汤含药肠吸收液组PMN-MDSCs的迁移距离均显著减小（

0.01），迁移及侵袭数量显著减少（

0.01），以26%含药肠吸收液组最为显著（

0.01）；与空白组比较，模型组PMN-MDSCs通路相关蛋白FAK、p-FAK、Src、p-Src表达显著升高（

0.01），VEGF、MMP-9细胞因子表达均显著上升（

0.01）。与模型组比较，FAK抑制剂组、半夏泻心汤含药肠吸收液组（26%、18%、10%）PMN-MDSCs FAK、p-FAK、Src蛋白表达降低（

0.01），FAK抑制剂组、半夏泻心汤含药肠吸收液组（18%）p-Src蛋白表达显著降低（

0.01），VEGF、MMP-9细胞因子表达显著降低（

0.01）。

结论

半夏泻心汤含药肠吸收液通过下调胃癌微环境PMN-MDSCs FAK信号通路蛋白FAK、p-FAK、Src、p-Src的表达，抑制PMN-MDSCs迁移侵袭。

Abstract

Objective

To observe the effect of Banxia Xiexintang containing intestinal absorption solution （BXCIAS） on migration and invasion of polymorphonuclear myeloid-derived suppressor cells （PMN-MDSCs） in gastric cancer microenvironment.

Method

The complex solution （containing 0.63 g·mL

-1

crude drug） was prepared. Gastric cancer cells were subjected to non-contact co-culture with PMN-MDSCs in Transwell chamber to create gastric cancer microenvironment. Cell counting kit-8 （CCK-8） assay was used to screen the optimal intervention concentration and time of BXCIAS on PMN-MDSCs for subsequent experiment. The blank group， model group， FAK inhibitor group， and BXCIAS groups （26%， 18%， and 10%） were designed. Scratch assay and Transwell assay were employed to detect the migration and invasion ability of PMN-MDSCs， and enzyme-linked immunosorbent assay （ELISA） to measure the expression of vascular endothelial cell growth factor （VEGF） and matrix metalloproteinase-9 （MMP-9） in tumor microenvironment. The expression levels of PMN-MDSCs pathway-related proteins FAK， phosphorylated （p）-FAK， protein tyrosine kinase （Src）， and p-Src were detected by Western blot.

Result

The inhibition rates of PMN-MDSCs by 5%， 50%， 75%， and 100% BXCIAS at 48 h were higher than those at 24 h （

0.05，

0.01）. The inhibition rate of PMN-MDSCs by 50% BXCIAS at 72 h was lower than that at 48 h （

0.01）， and the inhibition rates by 5% and 100% BXCIAS at 72 h were higher than those at 48 h （

0.05，

0.01）. There was no significant difference in the inhibition rate by other concentration levels at 48 h. The half-maximal inhibitory concentration （IC

） at 48 h was 18.09%， indicating that 18% BXCIAS and 48 h were the optimal concentration and time， respectively. The migration distance of PMN-MDSCs was large （

0.01）， and the number of migrating and invading cells increased （

0.01） in the mode group compared with those in the blank group. Compared with model group， FAK inhibitor and BXCIAS at different concentration decreased the migration distance of PMN-MDSCs （

0.01）， and the number of migrating and invading cells （

0.01）， especially the 26% BXCIAS （

0.01）. The expression of PMN-MDSCs pathway-related proteins FAK， p-FAK， Src and p-Src （

0.01） and the expression of VEGF and MMP-9 （

0.01） were higher in the model group than in the blank group. Compared with model group， FAK inhibitor and BXCIAS （26%， 18%， 10%） decreased the expression of FAK， p-FAK， and Src （

0.01）， and FAK inhibitor and 18% BXCIAS reduced the expression of p-Src （

0.01）， and the expression of VEGF and MMP-9 （

0.01）.

Conclusion

BXCIAS can inhibit the migration and invasion of PMN-MDSCs by down-regulating the expression of FAK， p-FAK， Src， and p-Src proteins in the FAK signaling pathway of PMN-MDSCs in gastric cancer microenvironment.

关键词

胃癌微环境髓源性抑制细胞半夏泻心汤黏着斑激酶（FAK）信号通路

Keywords

gastric cancer microenvironmentmyeloid-derived suppressor cellsBanxia XiexintangFAK signaling pathway

references

DU Y， ZHU H， LIU J， et al. Consensus on eradication of Helicobacter pylori and prevention and control of gastric cancer in China （2019， Shanghai）［J］. J Gastroenterol Hepatol， 2020， 35（4）： 624-629.

GABRILOVICH D I， NAGARAJ S. Myeloid-derived suppressor cells as regulators of the immune system ［J］. Nat Rev Immunol， 2009， 9（3）： 162-174.

TARTOUR E， PERE H， MAILLERE B， et al. Angiogenesis and immunity： A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy ［J］. Cancer Metastasis Rev， 2011， 30（1）： 83-95.

DE SANTO C， SERAFINI P， MARIGO I， et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination ［J］. Proc Natl Acad Sci USA， 2005， 102（11）： 4185-4190.

ELLIES L G， FISHMAN M， HARDISON J， et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase ［J］. Int J Cancer， 2003， 106（1）： 1-7.

KLEINSCHMIDT E G， SCHLAEPFER D D. Focal adhesion kinase signaling in unexpected places ［J］. Curr Opin Cell Biol， 2017， 45（3）： 24-30.

YAN H， ZHENG C， LI Z， et al. NPTX1 promotes metastasis via integrin/FAK signaling in gastric cancer ［J］. Cancer Manag Res， 2019， 11（4）： 3237-3251.

张成晶，朱许丽，张颖慧，等.基于寒热错杂病机中医药在胃癌各阶段防治中的研究［J］.中国中医基础医学杂志，2018，24（4）：510-512，532.

陶飞宝. 半夏泻心汤加味治疗胃癌20例疗效观察［J］. 实用中西医结合临床， 2013， 13（5）： 40-42.

崔国宁，刘喜平，陈嘉慧，等. 半夏泻心汤联合IL-12转染骨髓间充质干细胞对胃癌荷瘤裸鼠抑瘤作用研究［J］. 中国中医药信息杂志， 2020， 27（1）： 39-44.

李东峰，赵闻平，刘喜平，等. 半夏泻心汤含药血清对人胃癌腹膜转移细胞增殖的影响［J］. 西部中医药， 2014， 27（1）： 14-16.

刘喜平，李沛清，明海霞，等. 半夏泻心汤含药血清对胃癌腹膜转移细胞系GC9811-P增殖及侵袭转移的影响［J］. 中国中西医结合杂志， 2016， 36（10）： 1224-1228.

董俊刚，刘喜平，李沛清，等. 半夏泻心汤含药血清对胃癌细胞来源外泌体诱导BMSCs增殖、迁移、侵袭的影响［J］. 中成药， 2022， 44（1）： 42-48.

邓中甲.方剂学［M］.北京：中国中医药出版社，2003： 88.

张旻昱，龚慕辛，杨洪军. 含药肠吸收液：一种新的中药体外药理实验方法［J］. 中草药， 2018， 49（15）： 3457-3462.

WU Q， ZHOU L， LV D， et al. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression ［J］. J Hematol Oncol， 2019， 12（1）： 53-55.

华宏军，陈萍，叶晓华，等. FAK抑制剂PF573228负调控CD15s抑制肝癌细胞侵袭的作用机制研究［J］. 浙江医学， 2021， 43（6）： 600-605，93.

BINNEWIES M， ROBERTS E W， KERSTEN K， et al. Understanding the tumor immune microenvironment （TIME） for effective therapy ［J］. Nat Med， 2018， 24（5）： 541，550.

BRONTE V， BRANDAU S， CHEN S H， et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards ［J］. Nat Commun， 2016， 7（5）： 121-150.

PEINADO H， LAVOTSHKIN S， LYDEN D. The secreted factors responsible for pre-metastatic niche formation： Old sayings and new thoughts ［J］. Semin Cancer Biol， 2011， 21（2）： 139-146.

SAFARZADEH E， ORANGI M， MOHAMMADI H， et al. Myeloid-derived suppressor cells： Important contributors to tumor progression and metastasis ［J］. J Cell Physiol， 2018， 233（4）： 3024-3036.

何帅，蔺明煊，姜亦南，等. 中药成分肠吸收模型研究进展与思考［J］. 中医药学报， 2018， 46（3）： 121-124.

LIU Y， LAI L， CHEN Q， et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN ［J］. J Immunol， 2012， 188（11）： 5500-5510.

YANG L，DEBUSK L M，FUKUDA K，et al.Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis［J］.Cancer Cell，2004，6（4）：409-421.

YANG L，HUANG J，REN X，et al.Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis［J］.Cancer Cell，2008，13（1）：23-35.

BERG T J，PIETRAS A. Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells［J］.Semin Cancer Biol，2022，86（Pt 3）：846-856.

APTE R S， CHEN D S， FERRARA N. VEGF in signaling and disease： Beyond discovery and development ［J］. Cell， 2019， 176（6）： 1248-1264.

TALMADGE J E， GABRILOVICH D I. History of myeloid-derived suppressor cells ［J］. Nat Rev Cancer， 2013， 13（10）： 739-752.

MADLAMBAYAN G J， BUTLER J M， HOSAKA K， et al. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger ［J］. Blood， 2009， 114（19）： 4310-4319.

NGUYEN B T，PYUN J C，LEE S G，et al.Identification of new binding proteins of focal adhesion kinase using immunoprecipitation and mass spectrometry［J］.Sci Rep，2019，9（1）：12908.

HERRAIZ T， GALISTEO J. Tetrahydro-beta-carboline alkaloids that occur in foods and biological systems act as radical scavengers and antioxidants in the ABTS assay ［J］. Free Radic Res， 2002， 36（8）： 923-928.

PAN M R， HOU M F， OU-YANG F， et al. FAK is required for tumor metastasis-related fluid microenvironment in triple-negative breast cancer［J］. J Clin Med， 2019， 8（1）：38-43.

DEVAUD C， TILKIN-MARIAME A F， VIGNOLLE-VIDONI A， et al. FAK alternative splice mRNA variants expression pattern in colorectal cancer［J］. Int J Cancer， 2019， 145（2）：494-502.

ROY S， RUEST P J， HANKS S K. FAK regulates tyrosine phosphorylation of CAS， paxillin， and PYK2 in cells expressing v-Src， but is not a critical determinant of v-Src transformation［J］. J Cell Biochem， 2002， 84（2）：377-388.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Banxia Xiexintang-containing Intestinal Absorption Solution on PMN-MDSCs Apoptosis in Gastric Cancer Microenvironment

Pathogenesis of Spleen and Stomach Diseases and Therapeutic Effect of Banxia Xiexintang Based on Theory of "Mutual Interference of Clear and Turbid Qi" in Huangdi Neijing

Mechanism on Banxia Xiexintang Inducing Ferroptosis in Gastric Cancer Cells Based on Nrf2/GPX4 Signaling Pathway

Clinical Efficacy of Modified Banxia Xiexintang Combined with Vedolizumab in Treatment of Crohn's Disease with Syndrome of Cold and Heat in Complexity

Related Author

WEI Jingjing

ZHU Zhongbo

LIU Xiping

LI Peiqing

CHEN Qiming

DAI Lirong

SHI Lijuan

DUAN Haijing

Related Institution

Wangjing Hospital，China Academy of Chinese Medical Sciences

Henan Province Hospital of TCM/The Second Affiliated Hospital of Henan University of Chinese Medicine

Henan University of Chinese Medicine

School of Rehabilitation， Shandong University of TCM

Experimental Center of Shandong University of TCM

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰